Article detail · 2022 · article
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Journal
Irish Journal of Medical Science
ISSN0021-1265
YÖKSİS
OpenAlex
Open access · bronze
Top 10%
Year2022
Citations28OpenAlex
Citations23Semantic Scholar · 2 influential
Percentile%90.5
FWCI2.441.00 = world average
Scopus (SJR)Q3
WoS (JCR)Q3
Data source split
- YÖKSİSYÖKSİS article record
- YÖKSİS venueIrish Journal of Medical Science (1971 -)
- Catalog match (ISSN)Irish Journal of Medical Science
- OpenAlexOpenAlex enrichment (abstract, citations, topics)
- Semantic Scholarcitation count (not merged with OpenAlex)
Abstract
Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
28citationsOpenAlex · cited_by_count (cache / database)
4 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- 2023 Treatment of type 2 diabetes patients with heart conditionsCitations 47 · OpenAlex
- 2023 Treatment of type 2 diabetes patients with heart conditionsCitations 46 · OpenAlex
- 2024 Effect of sodium glucose Co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patientsCitations 20 · OpenAlex
- 2025 Investigation of the effect of SGLT-2 inhibitors on the triglyceride/glucose index in diabetic patients: a cross-sectional studyCitations 1 · OpenAlex